ADP-0000-001-SCR
Phase N/A
OPEN TO ACCRUAL
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies
ALLIANCE-A151804
Phase N/A
OPEN TO ACCRUAL
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
ALLIANCE-A222004-ANOREXIA
Phase III
OPEN TO ACCRUAL
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
ALLOVIR-AVM-003-HC
Phase III
OPEN TO ACCRUAL *
Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients with Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Cell Transplant
CTN-1705
Phase III
OPEN TO ACCRUAL
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1- Antitrypsin (AAT) Combined with Corticosteroids vs. Corticosteroids Alone for the Treatment of High-Risk Acute Graft-versus-Host-Disease (GVHD) Following Hematopoietic Stem Cell Transplant
IIT-RUNAAS-TILDRAKIZUMAB-AGVHD
Phase II
OPEN TO ACCRUAL
A Phase II Trial of Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
INCYTE-INCB-39110-211-CRS
Phase II
OPEN TO ACCRUAL
A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome (CRS) Induced by Immune Effector Cell Therapy